IDEXX Laboratories (NASDAQ:IDXX) Announces FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 14.960-15.160 for the period, compared to the consensus EPS estimate of 14.860. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Trading Up 3.9%

Shares of IDXX stock opened at $698.55 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.87 and a current ratio of 1.19. The business’s fifty day moving average is $541.78 and its 200 day moving average is $573.62. The company has a market capitalization of $55.04 billion, a PE ratio of 47.10 and a beta of 1.55. IDEXX Laboratories has a 52-week low of $500.61 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the firm posted $3.22 earnings per share. IDEXX Laboratories’s quarterly revenue was up 9.9% on a year-over-year basis. On average, equities research analysts anticipate that IDEXX Laboratories will post 15.06 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Citigroup lifted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. The Goldman Sachs Group started coverage on IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price target on the stock. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $719.55.

Insider Transactions at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.